2026 Asia AI Awards Ceremony
Innobo Therapeutics Wins Korea Venture Business Association Chairman's Award
Deepjema Identifies Candidate for Inflammatory Bowel Disease Treatment

Innobo Therapeutics won the Chairman of the Korea Venture Business Association Award at the 2026 Asia AI Awards ceremony held on November 5 at the Korea Press Center in Jung-gu, Seoul. The company was recognized for combining its experience in synthetic drug development with its proprietary artificial intelligence (AI) platform to identify drug candidates and advance them to clinical trials and technology-transfer deals.

Park Heedong, CEO of Innovo Therapeutics, poses for a commemorative photo after receiving the Venture Business Association Chairman's Award at the 2026 Asia AI Awards ceremony at the Press Center in Jung-gu, Seoul, on Nov. 5, 2026. Photo by Kang Jinhyeong

Park Heedong, CEO of Innovo Therapeutics, poses for a commemorative photo after receiving the Venture Business Association Chairman's Award at the 2026 Asia AI Awards ceremony at the Press Center in Jung-gu, Seoul, on Nov. 5, 2026. Photo by Kang Jinhyeong

View original image

Founded in 2019, Innobo Therapeutics develops treatments for immune and inflammatory diseases, fibrosis, and cancer. Its proprietary AI drug discovery platform, Deepjema, predicts which targets a compound may act on in the human body, as well as its potential properties and toxicity, helping the company narrow down its research targets. Deepjema is also used to identify whether substances already under study could potentially be used to treat other diseases.


A leading example is INV-008, a candidate treatment for inflammatory bowel disease. Using Deepjema, Innobo Therapeutics identified the candidate just 18 months after beginning research and signed a technology-transfer agreement with Daewoong Pharmaceutical in May 2026. The deal is worth up to 662.5 billion won, including an upfront payment and royalties tied to development milestones.


INV-001, a scar treatment, is an example of using AI to find a new use for an existing drug and advance it to clinical development. According to the company, it completed Phase 2 clinical trials in about four years and seven months after development began. In June 2026, it received approval from the Ministry of Food and Drug Safety for its Phase 3 clinical trial plan. Of the nine drug development programs secured by Innobo Therapeutics, four have entered the clinical stage.



Park Heedong, CEO of Innobo Therapeutics, said, "We are pursuing synthetic drug research and development by combining our accumulated drug development experience with our AI drug discovery platform, connecting AI technology to tangible drug development results and commercialization."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing